Harnessing the untapped potential of nucleotide-binding oligomerization domain ligands for cancer immunotherapy.

ABSTRACT: In the last decade, cancer immunotherapy has emerged as an effective alternative to traditional therapies such as chemotherapy and radiation. In contrast to the latter, cancer immunotherapy has the potential to distinguish between cancer and healthy cells, and thus to avoid severe and intolerable side-effects, since the cancer cells are effectively eliminated by stimulated immune cells. The cytosolic nucleotide-binding oligomerization domains 1 and 2 receptors (NOD1 and NOD2) are important components of the innate immune system and constitute interesting targets in terms of strengthening the immune response against cancer cells. Many NOD ligands have been synthesized, in particular NOD2 agonists that exhibit favorable immunostimulatory and anticancer activity. Among them, mifamurtide has a

SUBMITTER: Nabergoj S 

PROVIDER: S-EPMC6767550 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature